The approval was obtained by Grand Pharmaceutical Group Limited (“Grand Pharma”), Tarsus’ exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

Add Yahoo as a preferred source to see more of our stories on Google. Waking up with some gunk in your eyes is usually nothing to worry about. The scientific name for this crust is rheum, and it forms ...

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) said it will receive a $15 million milestone payment after China’s National Medical Products Administration approved TP-03 (lotilaner ophthalmic solution) ...

Blepharitis is a common condition that presents ophthalmologists with several challenges. Despite the frequency with which patients report symptoms of this condition, it remains largely underdiagnosed ...

The human skin surface is known to house millions of bacteria, though some people have more than the average number. Blepharitis is a bacterial infection that causes inflammation of the eyelids. The ...

(Yicai) March 23 -- Shares in Grand Pharma tumbled today despite the Chinese drugmaker being given the greenlight to take its first-in-class eye treatment for demodex blepharitis, a chronic eyelid ...

Please provide your email address to receive an email when new articles are posted on . It is predicted that as many as 70 to 80 million Americans have blepharitis of some type, and the sequelae ...

Neda Shamie, MD, summarizes the prevalence and clinical manifestations of Demodex Blepharitis. This is a video synopsis/summary of an Insights involving Neda Shamie, MD. Until recently, there were no ...